Clinical trial · Observational
Curcumin Bioavailability in Glioblastoma Patients
Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients
NCT01712542CI-TRIAL-00010529completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patient Harboring Glioblastoma That Will Undergo Surgery | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Concentration of Curcumin in Glioblastoma
- timeFrame
- At Tumor resection
- description
- At the time of surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients harboring Glioblastoma * Patient will undergo surgery Exclusion Criteria: * BMI \> 30 * Liver and Kidney Function so compromised that medication is prescribed
References
Publications (1)
- BACKGROUNDSenft C, Polacin M, Priester M, Seifert V, Kogel D, Weissenberger J. The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer. 2010 Sep 14;10:491. doi: 10.1186/1471-2407-10-491. PMID 20840775